JP2004524316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004524316A5 JP2004524316A5 JP2002567934A JP2002567934A JP2004524316A5 JP 2004524316 A5 JP2004524316 A5 JP 2004524316A5 JP 2002567934 A JP2002567934 A JP 2002567934A JP 2002567934 A JP2002567934 A JP 2002567934A JP 2004524316 A5 JP2004524316 A5 JP 2004524316A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- compound according
- methyl
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- -1 piperid-1-yl Chemical group 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000008447 perception Effects 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10108752A DE10108752A1 (de) | 2001-02-23 | 2001-02-23 | Neue Substituierte Imidazotriazinone |
| PCT/EP2002/001392 WO2002068423A1 (de) | 2001-02-23 | 2002-02-11 | Neue substituierte imidazotriazinone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004524316A JP2004524316A (ja) | 2004-08-12 |
| JP2004524316A5 true JP2004524316A5 (enExample) | 2005-12-22 |
Family
ID=7675248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567934A Pending JP2004524316A (ja) | 2001-02-23 | 2002-02-11 | 新規置換イミダゾトリアジノン類 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6998402B2 (enExample) |
| EP (1) | EP1363912B1 (enExample) |
| JP (1) | JP2004524316A (enExample) |
| CA (1) | CA2438890A1 (enExample) |
| DE (2) | DE10108752A1 (enExample) |
| ES (1) | ES2265487T3 (enExample) |
| WO (1) | WO2002068423A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| HRP20050848A2 (en) * | 2003-03-04 | 2006-06-30 | Altana Pharma Ag | Purin-6-one-derivatives |
| DE10320785A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
| US8044060B2 (en) | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
| US7226915B2 (en) | 2003-05-15 | 2007-06-05 | Hoffmann-La Roche Inc. | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors |
| CN100334088C (zh) * | 2003-05-15 | 2007-08-29 | 霍夫曼-拉罗奇有限公司 | 作为蛋白质酪氨酸磷酸酶抑制剂的二氨基吡咯并喹唑啉化合物 |
| JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体 |
| DE10328479A1 (de) | 2003-06-25 | 2005-01-13 | Bayer Ag | 6-Arylamino-5-cyano-4-pyrimidinone |
| DE102004001873A1 (de) | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
| US8648085B2 (en) | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CN102143965A (zh) | 2008-09-08 | 2011-08-03 | 贝林格尔.英格海姆国际有限公司 | 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途 |
| JP5503877B2 (ja) * | 2009-01-30 | 2014-05-28 | 住友化学株式会社 | ジベンゾオキセピン化合物の製造方法 |
| UY32531A (es) | 2009-03-31 | 2010-10-29 | Boehringer Ingelheim Int | Nuevos compuestos para el tratamiento de trastornos del snc |
| BR112013003097B1 (pt) | 2010-08-12 | 2021-03-16 | Boehringer Ingelheim International Gmbh | 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 製剤および医薬組成物 |
| EP3134413B1 (en) | 2014-04-23 | 2019-09-11 | Dart NeuroScience (Cayman) Ltd. | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors |
| TWI568737B (zh) | 2014-11-05 | 2017-02-01 | 達特神經科學（開曼）有限責任公司 | 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物 |
| BR112017012007B1 (pt) | 2014-12-06 | 2022-11-01 | Intra-Cellular Therapies, Inc | Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2 |
| WO2016090382A1 (en) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2017000276A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227841B1 (en) | 1997-11-12 | 2012-05-02 | Bayer Pharma AG | 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof |
-
2001
- 2001-02-23 DE DE10108752A patent/DE10108752A1/de not_active Withdrawn
-
2002
- 2002-02-11 JP JP2002567934A patent/JP2004524316A/ja active Pending
- 2002-02-11 DE DE50206892T patent/DE50206892D1/de not_active Expired - Fee Related
- 2002-02-11 EP EP02704706A patent/EP1363912B1/de not_active Expired - Lifetime
- 2002-02-11 WO PCT/EP2002/001392 patent/WO2002068423A1/de not_active Ceased
- 2002-02-11 CA CA002438890A patent/CA2438890A1/en not_active Abandoned
- 2002-02-11 ES ES02704706T patent/ES2265487T3/es not_active Expired - Lifetime
- 2002-02-11 US US10/468,511 patent/US6998402B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005502635A5 (enExample) | ||
| JP2002513793A5 (enExample) | ||
| JP2003531118A5 (enExample) | ||
| JP2011505347A5 (enExample) | ||
| JP2007502804A5 (enExample) | ||
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| JP2008512380A5 (enExample) | ||
| JP2005519908A5 (enExample) | ||
| JPH10279578A5 (enExample) | ||
| RU2002114337A (ru) | 4-фенилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норадреналина, допамина и серотонина | |
| JP2013507415A5 (enExample) | ||
| JP2010524939A5 (enExample) | ||
| JP2003528918A5 (enExample) | ||
| JP2011511075A5 (enExample) | ||
| JP2010505783A5 (enExample) | ||
| RU99101081A (ru) | Режим введения ингибиторов н+, к+-атфазы | |
| JP2005535675A5 (enExample) | ||
| JP2002505286A5 (enExample) | ||
| JP2012513390A5 (enExample) | ||
| JP2005538111A5 (enExample) | ||
| JP2005521676A5 (enExample) | ||
| JP2005500370A5 (enExample) | ||
| JP2004523478A5 (enExample) | ||
| JP2007515467A5 (enExample) | ||
| JP2020534266A5 (enExample) |